Immunoglobulin E specific for Artemisia californica pollen allergens (sIgE (Artemisia californica))

Immunoglobulin E (IgE) antibodies specific for Artemisia californica pollen allergens are the primary mediators of Type I hypersensitivity reactions to California sagebrush (Artemisia californica) (PMID: 16751541). These antibodies are produced by plasma cells following sensitization to specific protein components of the pollen, such as defensin-like proteins or profilins (PMID: 11398088). When an individual is re-exposed to the pollen, the allergens cross-link the IgE molecules bound to the high-affinity FcεRI receptors on the surface of mast cells and basophils (PMID: 24360961). This cross-linking triggers the immediate release of inflammatory mediators, including histamine and leukotrienes, which cause the clinical symptoms of allergic rhinitis and asthma (PMID: 12487219). Therapeutic interventions often focus on neutralizing these IgE antibodies using monoclonal antibodies like Omalizumab, which binds to the Fc region of free IgE, preventing its interaction with receptors (FDA Label: Xolair). Additionally, allergen-specific immunotherapy (AIT) aims to shift the immune response from a Th2-mediated IgE production toward a Th1/Treg-mediated response, increasing protective IgG4 levels (PMID: 28041614). Monitoring levels of these specific IgE antibodies is crucial for diagnosing California sagebrush allergy and assessing the efficacy of treatment (PMID: 16751541). The target is central to the pathophysiology of seasonal pollinosis in regions where Artemisia californica is prevalent.

Other names

California sagebrush-specific IgEAnti-Artemisia californica IgEIgE to Art c allergensArtemisia californica-specific Immunoglobulin E

Neutralization of circulating IgE and prevention of binding to high-affinity FcεRI receptors on effector cells.